Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis.
CardioVascular Center, Division of Cardiology, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
Adeeb H
AH
Al-Quthami
Marwan
M
Jumean
Robb
R
Kociol
Duc Thinh
DT
Pham
Michael
M
Kiernan
David
D
DeNofrio
Navin K
NK
Kapur
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D009202:Cardiomyopathies / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D004317:Doxorubicin / Q000009:adverse effects; D016903:Drug Monitoring / Q000379:methods; D000077542:Eptifibatide; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013927:Thrombosis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D016277:Ventricular Function, Left
D000903:Antibiotics, Antineoplastic; D005343:Fibrinolytic Agents; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D004317:Doxorubicin; D000077542:Eptifibatide